Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Author: kodiac

R-13

Our opinion on this compoundNovel, promising

64/100

Best-in-class oral TrkB agonist prodrug with dual AEP mechanism, Phase 1 complete but human efficacy unproven

The parent compound, 7,8-DHF (tropoflavin), has been circulating in the BDNF-mimetic space since around 2010, when the Ye lab first characterized TrkB agonism in Nature Neuroscience. The problem was always pharmacokinetics: rapid hepatic conjugation leaves almost nothing orally bioavailable, and brain concentrations after oral dosing are marginal. R-13 is the medicinal chemistry answer to that. It was selected from twenty candidate carbamate and ester derivatives as the only one that cleared all five screening gates simultaneously. Thats not trivial optimization work; most prodrug programs fail at one gate or another, and the fact that R-13 roughly doubles oral bioavailability over the parent while sustaining brain 7,8-DHF concentrations above 8 ng/g for four-plus hours is a real pharmacokinetic win.

What we like about the mechanism goes beyond TrkB activation. The AEP/delta-secretase repression angle is genuinely interesting. AEP cleaves both amyloid precursor protein and tau in pathological ways, and the fact that sustained TrkB signaling feeds back to repress that protease gives you two independent hits on Alzheimer’s pathophysiology from a single compound. The SOD1-G93A data adds a third logic: AMPK/PGC-1alpha/Nrf1/Tfam driven mitochondrial biogenesis as a motor neuron protection strategy. These are not the same mechanism dressed up in different names; they’re orthogonal effects across genuinely different disease contexts.

The preclinical package is one of the more complete ones we’ve reviewed for a small-molecule TrkB agent. The 5XFAD work covers spine density, long-term potentiation, plaque burden, neuroinflammatory cytokines, and behavioral readouts over 12 weeks of continuous dosing. The ALS data in SOD1-G93A is independent validation in a disease with completely different pathophysiology. That breadth matters because it makes the mechanism look durable rather than model-specific.

The evidence ceiling is where the score lands where it does. Chen and Ye (Emory/Zhejiang) remain the dominant research group. Replication outside that consortium is thin. Phase 1 completion confirms the compound is probably safe and orally active in humans, but thats the weakest form of clinical signal. We dont have efficacy data, and Phase 2 in Alzheimer’s is where the graveyard fills. The BDNF axis has a poor clinical track record broadly, and disease heterogeneity in AD makes outcomes hard to predict even with solid preclinical data.

The research bench value here is concrete. If you’re running any program that requires chronic oral TrkB activation in a living animal, R-13 is currently the best tool available. The parent 7,8-DHF is short-lived and inconsistent; the TrkB antibody agonists are expensive and non-oral; the neurotrophin peptides don’t cross the blood-brain barrier. R-13 fills a real gap as a probe, separate from whether it ever becomes a drug. We think it belongs in any BDNF/TrkB or AEP biology program, with eyes open to the Phase 2 uncertainty ahead.

Novelty

65

Mechanism promise

78

In-category differentiation

72

Evidence quality

48

Translational signal

42

Research bench value

72

Rationale R-13 scores well on novelty, mechanism, and differentiation because it is the first TrkB agonist small molecule to reach Phase 1 clinical evaluation and the only oral prodrug candidate to satisfy all bioavailability screening criteria from a 20-compound optimization series; the AEP/delta-secretase dual mechanism is genuinely interesting beyond simple TrkB agonism. Evidence and translational scores are held down by single-consortium dominance (Chen/Ye at Emory/Zhejiang) and the absence of Phase 2 efficacy data in any indication, with the historically poor bench-to-clinic track record for CNS BDNF-axis drugs adding real uncertainty.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Flavonoid-derived carbamate prodrug of 7,8-dihydroxyflavone with selective tropomyosin receptor kinase B agonist activity

A rationally designed bis-carbamate prodrug of 7,8-dihydroxyflavone engineered for improved oral bioavailability and sustained brain-derived neurotrophic factor receptor activation, advancing through Phase 1 clinical evaluation for Alzheimer’s disease and under preclinical investigation for amyotrophic lateral sclerosis, depression, Parkinson’s disease, and peripheral nerve regeneration.

Abstract

R-13 (BrAD-R13, Braegen-01) is a synthetic bis-methylcarbamate prodrug of 7,8-dihydroxyflavone (7,8-DHF; tropoflavin), designed to overcome the poor oral bioavailability and rapid hepatic conjugation of the parent flavone while preserving its selective agonist activity at the tropomyosin receptor kinase B (TrkB) receptor, the principal high-affinity signaling receptor for brain-derived neurotrophic factor (BDNF). The compound was identified through systematic medicinal chemistry optimization of ester and carbamate modifications on the 7,8-DHF catechol ring by Chen, Ye, and colleagues at Emory University School of Medicine and Zhejiang University, with R-13 selected from among twenty candidate derivatives as the sole compound satisfying all screening criteria for gastric acid stability, intestinal absorption, hydrolyzability in liver microsomes and plasma, and adequate membrane permeability. Following oral administration, R-13 is hydrolyzed through a monophenol intermediate (designated T1) to release 7,8-DHF, which binds the extracellular domain of TrkB and triggers receptor dimerization, autophosphorylation, and activation of the downstream Akt and ERK/MAPK signaling cascades. In mice, R-13 at 36 mg/kg oral dose produces a maximum plasma concentration of 129 ng/mL at 30 minutes, with an elimination half-life of approximately 220 minutes and oral bioavailability of 10.5 percent (compared to 4.6 percent for the parent 7,8-DHF), and sustains brain 7,8-DHF concentrations above 8 ng/g for at least 4 hours. The pharmacological consequences of sustained TrkB activation are broad: R-13 represses asparagine endopeptidase (AEP, also termed delta-secretase), a protease implicated in the pathological cleavage of both amyloid precursor protein and tau in Alzheimer’s disease, thereby reducing amyloid-beta deposition and neurofibrillary tangle formation. Chronic oral administration of R-13 in the 5XFAD transgenic mouse model of Alzheimer’s disease dose-dependently restored dendritic spine density, enhanced long-term potentiation, reduced senile plaque burden, attenuated neuroinflammatory cytokine levels (interleukin-1-beta, interleukin-6, tumor necrosis factor alpha), and reversed spatial and working memory deficits in the Morris water maze without demonstrable toxicity at 12 weeks of continuous dosing at up to 43.6 mg/kg/day. Additional preclinical evidence supports efficacy in the SOD1-G93A transgenic mouse model of amyotrophic lateral sclerosis, where R-13 preserved motor neuron counts, reduced gastrocnemius muscle atrophy, attenuated glial activation, and enhanced mitochondrial biogenesis through AMPK/PGC-1-alpha/Nrf1/Tfam pathway activation. In a peripheral nerve transection model, oral R-13 produced axon regeneration and functional electromyographic recovery superior to the parent 7,8-DHF. R-13 has also been characterized as preventing ovariectomy-induced bone loss through TrkB/Akt-mediated inhibition of AEP and upregulation of osteoprotegerin. Braegen Pharmaceutical (Shenzhen, China) has completed a Phase 1 clinical trial of BrAD-R13 in Alzheimer’s disease, the first clinical evaluation of a TrkB agonist prodrug in this indication, with plans for Phase 2 efficacy trials. The compound is not approved in any jurisdiction for any indication. This monograph reviews the chemistry, synthesis, and prodrug design of R-13; the TrkB receptor pharmacology and downstream signaling; the comprehensive preclinical pharmacokinetic profile; the evidence base across Alzheimer’s disease, amyotrophic lateral sclerosis, peripheral nerve injury, bone metabolism, and neuropsychiatric indications; sourcing and handling for research applications; stack-interaction considerations; adverse-event signal; and a comparative assessment of five alternative TrkB agonist and BDNF-mimetic candidates against R-13 on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1489Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 13, 2026
MitoQ

Plain-language summaryIntrigue 75 / 100

MitoQ is mitochondria-targeted ubiquinone (a derivative of CoQ10 with a positively charged triphenylphosphonium group that drives accumulation in mitochondria). Concentrates antioxidant activity at the mitochondrial inner membrane where oxidative damage occurs. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

55/100

Most-tested mito-targeted antioxidant; real vascular signal undercut by null Parkinson’s result and consistently small trial Ns

MitoQ sits in an interesting position for a compound that’s now 30 years old. The TPP+ targeting chemistry Robin Smith and Michael Murphy worked out at Otago in the 1990s is still the most elegant solution to a genuine problem: conventional CoQ10 doesn’t accumulate in mitochondria at therapeutically meaningful concentrations, but MitoQ gets there at 100- to 500-fold above extracellular levels, driven by membrane potential. We like that the mechanism is genuinely catalytic. The ubiquinol form gets recycled by complex II, so you’re not burning through a stoichiometric antioxidant pool the way you do with alpha-tocopherol analogs. That’s a real mechanistic distinction, not a marketing one.

The clinical record is the most complete in the mitochondria-targeted antioxidant class, which matters when competitors like elamipretide and SkQ1 are still largely preclinical or narrowly indicated. Four completed human trials. The standout is Rossman et al. 2018: a randomized crossover in 20 healthy older adults with impaired endothelial function, 6 weeks at 20 mg per day, 42 percent improvement in brachial artery flow-mediated dilation versus placebo, with concurrent reductions in oxidized LDL and aortic pulse wave velocity. That effect size is not trivial. The Gane et al. 2010 hepatitis C study added a hepatoprotective liver enzyme signal. The 2024 Jain COVID pilot is hypothesis-generating at best and we wouldnt count it heavily.

Here’s the thing: the PROTECT trial is important and we have to sit with it. A 128-patient, 12-month double-blind RCT in newly diagnosed Parkinson’s disease patients found zero difference between MitoQ and placebo on any outcome measure. That’s a well-powered null in the indication MitoQ was arguably most hyped for. It doesnt kill the compound in other contexts, but it does tell you that the oxidative stress hypothesis in early Parkinson’s is weaker than the preclinical story suggested, and it should temper enthusiasm for uncritical generalization to neurodegeneration models.

The Rossman vascular result needs replication at meaningful N before anyone builds a research program around it. Twenty healthy older adults in a crossover design is a start, not a conclusion. What we’d actually want is a 150- to 200-person confirmatory trial in the same vascular aging population before treating this as established. Until then, the human translational signal is real but fragile.

As a bench tool, MitoQ remains genuinely useful. It’s the reference probe for testing whether a phenotype in your model is mitochondrial-ROS-dependent. Nothing else delivers the same accumulation ratio with the same clinical cross-validation behind it. MitoTEMPO has probe utility in cell-free assays, but MitoQ has the more complete recycling mechanism and the human data. For labs investigating oxidative stress in cardiovascular, hepatic, or metabolic models, MitoQ is a serious tool. The 55 overall reflects what we think is the honest picture: class-leading human evidence and real mechanistic value, undercut by a null trial in the most-watched indication, consistently small N in the positive studies, and a core targeting strategy that’s three decades old and no longer the frontier of the field.

Novelty

42

Mechanism promise

60

In-category differentiation

60

Evidence quality

52

Translational signal

52

Research bench value

65

Rationale MitoQ leads the mitochondria-targeted antioxidant class on human clinical depth (four trials including a 128-patient RCT) but scores mid-range overall because the marquee PROTECT Parkinson’s trial was null, positive trials run 20-30 subjects, and the core TPP+ targeting chemistry is now 30 years old. Bench value is genuine as the reference probe for mitochondrial-ROS-dependent phenotyping in cardiovascular and metabolic models.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Mitochondria-targeted ubiquinone-derived antioxidant conjugated to a triphenylphosphonium cation

A synthetic coenzyme Q10 analog covalently linked to a lipophilic triphenylphosphonium moiety that drives selective mitochondrial accumulation, enabling targeted quenching of reactive oxygen species at the inner mitochondrial membrane with demonstrated vascular, hepatoprotective, and anti-inflammatory activity in human clinical studies.

Abstract

Mitoquinone mesylate (MitoQ) is a mitochondria-targeted antioxidant composed of a ubiquinone moiety covalently linked via a ten-carbon alkyl chain to a triphenylphosphonium (TPP+) cation, enabling rapid permeation of lipid bilayers and accumulation within the mitochondrial matrix at concentrations up to several hundred-fold above extracellular levels, driven by the large negative mitochondrial membrane potential (approximately negative 150 to negative 180 millivolts). The compound was developed in the 1990s by Robin Smith and Michael Murphy at the University of Otago, New Zealand, as an approach to overcoming the failure of conventional untargeted antioxidants (including native coenzyme Q10) to achieve therapeutically meaningful concentrations within mitochondria, the principal intracellular source of reactive oxygen species (ROS). Within the mitochondrion, MitoQ adsorbs to the matrix-facing leaflet of the inner mitochondrial membrane, where the ubiquinone head group is reduced to the active antioxidant ubiquinol form by complex II (succinate:ubiquinone oxidoreductase) of the electron transport chain. The ubiquinol form scavenges superoxide, hydroxyl radicals, and peroxyl radicals, preventing lipid peroxidation of cardiolipin and other mitochondrial membrane phospholipids. Following oxidation during radical quenching, the resulting ubiquinone is re-reduced by complex II, establishing a catalytic antioxidant cycle that permits repeated radical neutralization from a single molecule. This recycling mechanism distinguishes MitoQ from stoichiometric antioxidants such as alpha-tocopherol that are consumed in the quenching reaction. Preclinical pharmacology has demonstrated protective effects in rodent models of ischemia-reperfusion injury, diabetic nephropathy, nonalcoholic fatty liver disease, sepsis-associated organ failure, pulmonary hypertension, Alzheimer’s disease, doxorubicin-induced cardiomyopathy, cisplatin nephrotoxicity, and metabolic syndrome, with consistent reductions in mitochondrial oxidative damage markers, preservation of mitochondrial membrane potential, and attenuation of downstream inflammatory signaling through suppression of NF-kappaB activation and NLRP3 inflammasome assembly. Four completed human clinical trials define the current clinical evidence base. The Snow et al. (2010) PROTECT study, a 12-month randomized double-blind placebo-controlled trial in 128 newly diagnosed untreated Parkinson’s disease patients at 40 or 80 mg per day, found no difference between MitoQ and placebo on any measure of disease progression, establishing an important negative result for the oxidative stress hypothesis in early Parkinson’s disease. The Gane et al. (2010) phase II trial in 30 patients with chronic hepatitis C virus infection demonstrated significant decreases in serum alanine aminotransferase and aspartate aminotransferase at 40 and 80 mg per day over 28 days, without change in viral load, suggesting hepatoprotective activity through reduction of mitochondrial oxidative necroinflammation. The Rossman et al. (2018) randomized crossover trial in 20 healthy older adults (60 to 79 years) with impaired endothelial function demonstrated that 6 weeks of MitoQ at 20 mg per day produced a 42 percent improvement in brachial artery flow-mediated dilation versus placebo, with concurrent reductions in plasma oxidized low-density lipoprotein and aortic pulse wave velocity, establishing the first human evidence for mitochondria-targeted antioxidant improvement of age-related vascular dysfunction. A 2024 exploratory pilot trial (Jain et al. 2024) of MitoQ as post-exposure prophylaxis against SARS-CoV-2 infection reported reduced infection rates and symptom duration in the treatment group versus matched controls. The compound is well tolerated in human studies at doses up to 80 mg per day for 12 months, with nausea and gastrointestinal discomfort as the principal dose-limiting adverse events. MitoQ is not approved as a pharmaceutical by any regulatory authority; it is marketed globally as a dietary supplement at doses of 5 to 10 mg per day and is available as a research-grade compound from multiple chemical suppliers. This monograph reviews the chemistry, synthesis, and mitochondrial targeting mechanism of MitoQ; the comprehensive preclinical pharmacology across disease models; the complete human clinical evidence base; pharmacokinetics including the low oral bioavailability and extensive first-pass metabolism; sourcing, reconstitution, and handling; stack-interaction considerations; adverse-event signal; and a structured comparative assessment of five mitochondria-targeted antioxidant candidates (SkQ1, elamipretide, MitoTEMPO, MitoVitE, idebenone) against MitoQ on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1466Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 13, 2026
BAM15

Our opinion on this compoundNovel, promising

62/100

Mitochondrial-selective uncoupler with compelling metabolic preclinical data but no human trials yet

Look, the classical uncoupler problem is straightforward: DNP works, DNP also kills you. The mechanism is compelling but plasma membrane depolarization is a hard ceiling on the whole class. BAM15 is the first compound to credibly solve that problem at the scaffold level. The oxadiazolopyrazine core allows mitochondrial-selective proton gradient dissipation without collapsing the plasma membrane potential, and thats not a minor technical footnote. It’s the thing that makes a therapeutic uncoupler program viable at all.

The Kenwood 2014 phenotypic screen at UVA/Virginia Tech was searching for exactly this property, and BAM15 emerged as the lead hit. Alexopoulos et al. (2020) is where the metabolic pharmacology really landed: 100 mg/kg/day oral in HFD C57BL/6J mice reversed diet-induced obesity, cut hepatic triglycerides by roughly 75 percent, and improved insulin sensitivity on hyperinsulinemic-euglycemic clamp, without touching food intake or lean mass. That’s the profile you want. The head-to-head in db/db female mice is genuinely striking: BAM15 and calorie restriction outperformed semaglutide, niclosamide ethanolamine, and rosiglitazone on body weight and liver steatosis endpoints. That kind of direct comparator data gets investigators’ attention.

What we like beyond the metabolics: the preclinical breadth here is unusual for a compound still sitting on the shelf. Sepsis survival benefit 12 hours post cecal ligation and puncture. AML cell selectivity with ROS-mediated apoptosis sparing normal hematopoietic cells. Atherosclerosis suppression in ApoE-knockout mice through AMPK and NF-kappaB/NLRP3 suppression. Sarcopenia signal in aged mice with preserved skeletal muscle contractility. The AMPK/PGC-1alpha axis and mitochondrial dynamics connect these indications in a biologically coherent way, not just target-hunting.

What we dont like: no human data, at all. BAM15 has been in preclinical development since 2014 and hasn’t reached a phase 1 trial. The short half-life of 1.7 hours in mice and heavy hepatic distribution raise real PK questions that haven’t been answered in people. Hepatic selectivity that’s a feature for MASH could be a constraint for CNS or skeletal muscle indications. The history of uncouplers in the clinic is not reassuring, and translational risk for this class is genuinely elevated even with the improved safety index.

As a bench tool, though, BAM15 is about as useful as it gets for mitochondrial biology. It lets you cleanly dissect mitochondrial membrane potential from plasma membrane potential in ways that FCCP, at effective concentrations, simply cannot do safely. That probe utility is independent of the therapeutic story. We think BAM15 belongs in serious metabolic and mitochondrial research programs right now. But the 2014-to-still-no-IND timeline is a signal worth sitting with before you center a program on it.

Novelty

65

Mechanism promise

80

In-category differentiation

72

Evidence quality

42

Translational signal

32

Research bench value

70

Rationale BAM15 earns strong mechanism and differentiation scores for credibly solving the classical uncoupler toxicity problem through mitochondrial-selective proton gradient dissipation, backed by multi-indication preclinical breadth across metabolic, sepsis, oncology, and aging models; the overall is held back by zero human clinical data and a 2014 discovery date that limits novelty credit relative to bleeding-edge candidates.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Mitochondria-selective protonophore uncoupler of oxidative phosphorylation

A synthetic oxadiazolopyrazine-scaffold mitochondrial protonophore distinguished from classical uncouplers by selective dissipation of the inner mitochondrial membrane proton gradient without depolarization of the plasma membrane, conferring potent metabolic enhancement with markedly reduced cytotoxicity in preclinical models of obesity, insulin resistance, hepatic steatosis, sepsis, and cancer.

Abstract

BAM15 (N5,N6-bis(2-fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine) is a synthetic small-molecule mitochondrial protonophore first identified in a 2014 phenotypic screen by Kenwood et al. at the University of Virginia and Virginia Tech for compounds that uncouple mitochondrial oxidative phosphorylation without depolarizing the plasma membrane [1]. The compound dissipates the electrochemical proton gradient across the inner mitochondrial membrane, thereby uncoupling electron transport from adenosine triphosphate (ATP) synthesis and increasing substrate oxidation and energy expenditure. Unlike the classical protonophore uncouplers 2,4-dinitrophenol (DNP) and carbonylcyanide-p-trifluoromethoxyphenylhydrazone (FCCP), BAM15 selectively targets the mitochondrial membrane and does not collapse the plasma membrane potential at effective uncoupling concentrations, a property that confers a substantially wider therapeutic index and reduced cytotoxicity in cultured cells and in vivo [1, 2]. The compound is orally bioavailable in mice (67 percent oral bioavailability, Cmax 8.2 micromolar, t1/2 1.7 hours) with primary distribution to the liver, supporting hepatic metabolic applications [3]. In C57BL/6J mice fed a high-fat diet, BAM15 administered at 100 mg/kg/day by oral gavage reversed diet-induced obesity, decreased body fat mass without altering food intake or lean body mass, reduced hepatic triglycerides by approximately 75 percent, decreased inflammatory lipids, and improved whole-body insulin sensitivity as demonstrated by hyperinsulinemic-euglycemic clamp [3]. In a head-to-head comparison in female db/db mice, BAM15 and calorie restriction improved body weight and liver steatosis to levels superior to semaglutide, niclosamide ethanolamine (NEN), and rosiglitazone, while BAM15, semaglutide, and rosiglitazone completely restored glucose tolerance [4]. These metabolic effects are mediated through sustained activation of AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), promoting fatty acid oxidation, glucose uptake, and mitochondrial biogenesis [2, 5]. Beyond metabolic disease, BAM15 has demonstrated preclinical efficacy in acute kidney injury and sepsis (reducing mortality even when administered 12 hours after cecal ligation and puncture in mice) [6], in acute myeloid leukemia (inhibiting AML cell proliferation and inducing reactive oxygen species-mediated apoptosis with selectivity over normal cells) [7], in sarcopenic obesity (preserving skeletal muscle contractility and mitochondrial respiration in aged mice) [8, 9], in atherosclerosis (suppressing western diet-induced plaque formation in ApoE-knockout mice through AMPK activation and NF-kappaB/NLRP3 inflammasome suppression) [10, 11], and in vascular smooth muscle relaxation [5]. Safety pharmacology in rodents has demonstrated no alteration of body temperature, food intake, lean body mass, or standard hematological and biochemical markers of toxicity at effective metabolic doses [3]. BAM15 has not entered human clinical trials as of the most recent monograph revision. The compound is supplied as a research-grade material by multiple chemical suppliers at greater than 98 percent purity and is not approved by any regulatory authority for therapeutic use. This monograph documents the chemistry, synthesis, discovery history, molecular pharmacology, pharmacokinetics, preclinical evidence base across metabolic, inflammatory, oncologic, and aging indications, sourcing and quality verification, reconstitution and handling, stack-interaction considerations, adverse-event profile, and a structured comparative assessment against five alternative mitochondrial uncouplers.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1470Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 13, 2026
PRE-084

Our opinion on this compoundNiche research probe

51/100

The reference pharmacological probe for sigma-1R biology with broad but entirely preclinical reach

PRE-084 is the sigma-1 receptor reference tool, full stop. What Su and colleagues at NIDA built in 1991 was a compound stripped of PCP activity (IC50 greater than 100,000 nM at the PCP site) while retaining high-affinity sigma-1R binding around 44 nM, and that selectivity gap is what makes this compound genuinely useful as a probe. You can interrogate sigma-1R function without worrying that your read-out is contaminated by NMDA channel blockade. Thats a real advantage that most sigma ligands cant claim, including fluvoxamine, which brings a serotonin transporter story along for the ride whether you want it or not.

The sigma-1 receptor biology is why we find this worth stocking. It’s not a classic GPCR. It’s a ligand-operated chaperone at the mitochondria-associated ER membrane, where it shapes IP3R-mediated calcium transfer, feeds ER stress responses, and gates NF-kB, ERK/CREB, and PKC cascades depending on context. That’s a pharmacological handle distinct from receptor agonism in a saturated class, and PRE-084 lets you pull on it cleanly and interpret results without crosstalk artifacts.

The preclinical breadth is real and it comes from multiple labs. SOD1-G93A mice showed improved motoneuron survival and extended lifespan with daily PRE-084; the wobbler model confirmed the effect isn’t SOD1-specific, which matters for mechanistic generalizability. Add ischemic stroke, both 6-OHDA and MPTP Parkinson’s paradigms, MK-801 amnesia, amyloid-beta cognitive impairment, Huntington’s cellular degeneration via NF-kB-driven calpastatin, and myocardial ischemia-reperfusion. That’s an unusual disease portfolio for a compound sitting entirely at the preclinical stage. The common thread is sigma-1R’s role in proteostasis and calcium homeostasis under cellular stress, which is a genuinely interesting biological thesis.

Here’s where we have to be honest about the limits. PRE-084 has never been in a human. Not in a phase 1, not in a compassionate use program. The sigma-1R clinical story has been carried by other compounds entirely: SA4503 in depression, blarcamesine in Alzheimer’s, pridopidine in Huntington’s. Those programs have produced modest or mixed signals. That doesn’t invalidate the preclinical biology, but it should calibrate expectations about what this receptor class actually delivers in people. The translational arrow is weak for PRE-084 specifically.

We also note that the compound is 35 years old. novelty here lives in the target biology, not the molecule. For labs actively doing sigma-1R work, PRE-084 is still the probe of choice for clean mechanistic attribution. For labs asking whether sigma-1R agonism is worth pursuing at all, this is the compound you use to answer that question before committing to a more complex scaffold. That’s the case for stocking it: indispensable bench utility in a receptor class that’s still sorting out its clinical identity.

Novelty

35

Mechanism promise

65

In-category differentiation

63

Evidence quality

43

Translational signal

28

Research bench value

75

Rationale PRE-084 earns its place on bench-value grounds alone: 2000-fold selectivity over the PCP site makes it the cleanest sigma-1R probe available, and the preclinical literature spans at least ten disease contexts across multiple independent labs. What holds it back is a 1991 vintage, zero human data for this specific compound, and a clinical sigma-1R agonist class that has so far produced mixed-to-modest results.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective sigma-1 receptor agonist derived from phencyclidine with neuroprotective, nootropic, and neurotrophic activity

A phencyclidine-derived sigma-1 receptor agonist developed as a pharmacological tool compound, distinguished by high selectivity over sigma-2 and PCP receptors and by a broad preclinical literature spanning neuroprotection in motor neuron disease, stroke, Parkinson’s disease, cognitive impairment, and antidepressant activity.

Abstract

PRE-084 (2-(4-morpholino)ethyl 1-phenylcyclohexane-1-carboxylate) is a selective agonist of the sigma-1 receptor (sigma-1R) originally identified in 1991 by Su and colleagues at the National Institute on Drug Abuse through a systematic structure-activity program that sought to separate sigma receptor affinity from phencyclidine (PCP) receptor binding in the parent cyclohexylamine scaffold [1]. The compound binds the sigma-1 receptor with an IC50 of approximately 44 nM in radioligand displacement assays and exhibits selectivity ratios exceeding 2000-fold over the PCP binding site (IC50 greater than 100,000 nM) and approximately 300-fold over the sigma-2 receptor subtype (IC50 approximately 13,091 nM), establishing it as one of the most widely used pharmacological tools for interrogating sigma-1 receptor function in vitro and in vivo [1, 2]. The sigma-1 receptor itself is a ligand-regulated chaperone protein resident at the mitochondria-associated endoplasmic reticulum membrane (MAM), where it modulates calcium signaling through interactions with inositol 1,4,5-trisphosphate receptors, regulates protein folding and endoplasmic reticulum stress responses, and participates in diverse signal transduction cascades including the NF-kappaB, ERK/CREB, and protein kinase C pathways [3, 4]. PRE-084 has not been advanced to human clinical trials and carries no regulatory approval in any jurisdiction; its utility is exclusively as a research-grade pharmacological probe. The preclinical literature on PRE-084 is nonetheless substantial and spans multiple therapeutic domains. In amyotrophic lateral sclerosis, daily administration of PRE-084 to SOD1-G93A transgenic mice from eight weeks of age preserved spinal motoneuron survival, maintained compound muscle action potential amplitudes, improved locomotion, and extended overall survival, with neuroprotective effects attributed to protein kinase C-mediated phosphorylation of the NMDA receptor NR1 subunit and reduction of microglial reactivity [5, 6]. Comparable neuroprotection was demonstrated in the wobbler mouse model of motor neuron disease not linked to SOD1 mutation, broadening the mechanistic generalizability [7]. In ischemic stroke models, PRE-084 at 5 mg/kg intraperitoneally reduced infarct volume and neurological deficit scores after embolic middle cerebral artery occlusion in rats, with the mechanism involving suppression of pro-inflammatory cytokines (interleukin-1 beta, tumor necrosis factor alpha) and enhancement of anti-inflammatory cytokines [8]. In Parkinson’s disease models, PRE-084 administration normalized motor dysfunction and prevented dopaminergic neuron loss in both 6-hydroxydopamine and MPTP paradigms through sigma-1 receptor-mediated promotion of PINK1/Parkin mitophagy and enhancement of dopamine transporter expression [9, 10]. Cognitive and nootropic effects have been characterized across multiple paradigms: PRE-084 attenuated MK-801-induced amnesia, amyloid-beta peptide-induced learning impairment, and spatial learning deficits in aged rats, with mechanisms involving upregulation of NMDA receptor expression in the hippocampus and activation of the ERK/CREB/BDNF signaling axis [11, 12, 13]. Antidepressant-like activity has been demonstrated in the forced swim test in multiple mouse strains at doses of 30 to 60 mg/kg, with enhanced efficacy in amyloid-beta-treated animals [14, 15]. Additional preclinical applications include cardioprotection in myocardial ischemia-reperfusion injury, neuroprotection in perinatal excitotoxic brain injury, glial modulation in spinal muscular atrophy, protection against Huntington’s disease-associated cellular degeneration through NF-kappaB-mediated calpastatin upregulation, and attenuation of sepsis-associated encephalopathy [16, 17, 18, 19, 20]. Pharmacokinetic characterization in mice after intraperitoneal administration at 10 mg/kg reveals rapid central nervous system penetration (brain concentration 773.6 ng/g at five minutes), a plasma elimination half-life of approximately 195 minutes, and stability in biological matrices for at least 24 hours [2]. The compound is supplied as the hydrochloride salt by multiple research chemical vendors at greater than 98 percent purity and is reconstituted in aqueous solution or dimethyl sulfoxide for experimental use. This monograph reviews the chemistry, synthesis, and selectivity of PRE-084; the sigma-1 receptor chaperone pharmacology in molecular detail; the pharmacokinetic profile; the full preclinical evidence base across neurodegenerative, cerebrovascular, cognitive, affective, and cardioprotective domains; sourcing and quality verification; reconstitution and handling; stack interaction considerations; adverse event and safety signal from preclinical data; and a comparative assessment of five sigma-1 receptor candidates (SA4503/cutamesine, ANAVEX2-73/blarcamesine, pridopidine, igmesine, and fluvoxamine) against PRE-084 on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1464Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 13, 2026
Apigenin

Our opinion on this compoundNiche research probe

39/100

A multi-target dietary flavone with a genuine CD38/NAD+ research angle held back by modest selectivity and thin human evidence

Look, apigenin is one of those compounds that keeps showing up in interesting conversations without ever quite being the main event. The CD38 inhibition story is real, the GABA-A activity is real, the aromatase suppression is real, and the anti-inflammatory pharmacology is real. That’s a lot of legitimate mechanism for a molecule you can eat in a bowl of parsley. The problem isn’t that apigenin is boring. The problem is that for every mechanism it touches, there’s a more selective, more potent tool that serious investigators reach for first.

The CD38 angle is the most compelling part of the apigenin story right now. Camacho-Pereira and colleagues established CD38 as the dominant NADase driving age-related NAD+ decline, and apigenin inhibits it. That’s genuinely useful context for NAD+ biology research. But the Imai lab’s 78c compound and other more selective CD38 inhibitors have largely displaced apigenin as the probe of choice in that field. Apigenin’s IC50 at CD38 sits in the single-digit micromolar range in cell-free assays, which is respectable, but oral bioavailability complicates translating that into meaningful tissue concentrations in vivo, and the selectivity window is narrow.

The GABA-A story is modest. Apigenin shows benzodiazepine-site activity at reasonable concentrations in rodent models, and the anxiolytic and sedative effects are real and replicated. But binding affinity is weaker than classical benzodiazepines and most dedicated GABA-A pharmacological tools. The aromatase inhibition (IC50 roughly 20 to 23 micromolar) is competitive but sits in a class with dozens of natural and synthetic inhibitors. Theres nothing uniquely best-in-class here, and the NF-kappaB suppression is frankly a property shared by half the flavonoid family.

Evidence quality is a mixed story. The preclinical literature is genuinely extensive across multiple independent labs, which is more than most flavonoids can claim. Anti-cancer, neuroprotective, and metabolic endpoints have been replicated in multiple rodent systems. But the human evidence is almost entirely from chamomile extract trials, where apigenin is one active constituent among many. Isolating apigenin’s contribution from those trials is genuinely difficult, and dedicated clinical studies with isolated apigenin are sparse to the point of being nearly absent.

We think the best case for keeping apigenin in a research library is as a cheap, accessible multi-target probe that lets you simultaneously perturb CD38, GABA-A, and aromatase in the same experiment. For combination mechanistic work or screening contexts where cost and accessibility matter, it has real utility. For anyone seriously studying any one of those targets in isolation, better tools exist. The multi-target profile is double-edged: it creates combinatorial bench value, but it also makes clean mechanistic attribution hard. At 39, we’re saying it’s worth having access to, not worth centering a program around.

Novelty

30

Mechanism promise

52

In-category differentiation

38

Evidence quality

35

Translational signal

30

Research bench value

48

Rationale Apigenin’s multi-target profile (CD38, GABA-A, aromatase, NF-κB) earns it more than a plain dietary flavone designation, and the CD38/NAD+ angle qualifies as a novel indication with real preclinical signal that exempts it from the OTC food/herb cap; the natural score of 39 reflects that more selective probes exist for each individual target and human evidence for isolated apigenin remains sparse.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Trihydroxyflavone with multi-target activity spanning CD38 NADase inhibition, GABA-A receptor modulation, aromatase suppression, and broad anti-inflammatory and pro-apoptotic signaling

A dietary flavone abundant in chamomile, parsley, and celery, distinguished from other common flavonoids by potent CD38 NADase inhibition with consequent elevation of intracellular NAD+, moderate GABA-A receptor activity at the benzodiazepine site, competitive aromatase inhibition, and a broad preclinical pharmacology spanning anti-inflammatory, neuroprotective, anti-cancer, and metabolic endpoints.

Abstract

Apigenin (4′,5,7-trihydroxyflavone) is a naturally occurring flavone present at high concentration in chamomile flowers, parsley, celery, and numerous other dietary plant sources. It is one of the most extensively studied plant flavonoids, with a preclinical research literature encompassing anti-inflammatory, antioxidant, neuroprotective, anxiolytic, anti-cancer, cardioprotective, and metabolic activities. The compound is distinguished from the structurally related flavonoids quercetin, luteolin, and kaempferol by several pharmacological features of particular current research interest: potent inhibition of CD38, the principal mammalian NAD+-degrading ectoenzyme, resulting in elevation of intracellular nicotinamide adenine dinucleotide (NAD+) and consequent activation of sirtuin-dependent deacetylation pathways relevant to metabolic syndrome and aging; moderate activity at the benzodiazepine binding site of the gamma-aminobutyric acid type A (GABA-A) receptor, producing anxiolytic and sedative effects in rodent models; competitive inhibition of aromatase (CYP19A1) with an IC50 of approximately 20 to 23 micromolar, reducing estrogen biosynthesis; and suppression of NF-kappaB-driven proinflammatory cytokine production through multiple converging mechanisms including direct IKK-beta inhibition and modulation of the PI3K/AKT and MAPK/ERK signaling cascades.

The CD38 inhibitory activity, formally characterized by Escande et al. (2013) in a report from the Bhatt, Chini, and Sinclair laboratories, demonstrated that apigenin administration to obese mice increased tissue NAD+ levels, decreased global protein acetylation through sirtuin activation, and improved glucose and lipid homeostasis parameters [1]. This finding positioned apigenin within the NAD+ restoration research framework alongside nicotinamide mononucleotide and nicotinamide riboside, though through a mechanistically distinct pathway (reduced NAD+ degradation rather than precursor supplementation). The GABA-A receptor activity, first reported by Viola et al. (1995) using competitive radioligand displacement at the benzodiazepine site, produced anxiolytic effects in elevated plus maze and open field paradigms in mice without the sedation, amnesia, or muscle relaxation characteristic of classical benzodiazepines [2]. Subsequent electrophysiological and behavioral studies have produced conflicting characterizations of the precise nature of the GABA-A interaction, with reports variously describing apigenin as a weak partial agonist, an antagonist, or an inverse agonist at the benzodiazepine site depending on assay system and concentration.

Pharmacokinetics in humans are incompletely characterized. Oral bioavailability is estimated at approximately 30 percent, limited by poor aqueous solubility and extensive first-pass phase II conjugation (glucuronidation and sulfation). Phase I oxidative metabolism is mediated principally by CYP1A1, CYP1A2, and CYP2E1, producing the hydroxylated metabolite luteolin as the major oxidative product. The plasma elimination half-life after oral administration is approximately 2 to 3 hours in the limited human pharmacokinetic data available. Apigenin inhibits CYP2C9, CYP3A4, and P-glycoprotein in vitro at concentrations that may be clinically relevant at supplemental doses, raising drug-drug interaction considerations.

The compound is non-mutagenic and non-genotoxic in standard regulatory toxicology assays. No significant toxicity has been observed in animal studies at doses up to 50 mg/kg, though hepatotoxicity has been reported at intraperitoneal doses of 100 mg/kg and above in mice. Human safety data at supplemental doses (50 to 500 mg daily) are limited but have not produced serious adverse event signals. The principal reported adverse effects at supplemental doses are drowsiness (consistent with GABA-A activity) and mild gastrointestinal discomfort.

This monograph reviews the chemistry, natural sources, and isolation history of apigenin; the multi-target molecular pharmacology spanning CD38, GABA-A, aromatase, and inflammatory signaling; the available pharmacokinetic data in animals and humans; the preclinical pharmacology across neuroprotective, anti-cancer, anti-inflammatory, and metabolic endpoints; the limited clinical evidence base; sourcing and quality verification for research applications; reconstitution and handling; stack interactions; adverse events and safety; and a comparative assessment of five structurally or functionally related flavonoid compounds against apigenin on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1484Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 13, 2026
Boswellic-Acid

Our opinion on this compoundEstablished workhorse

42/100

Mechanistically distinct natural anti-inflammatory with genuine RCT data, but 30-year-old science that isn’t reshaping any current research frontier

Look, the allosteric 5-LOX inhibition story is legitimately interesting. AKBA binds 5-lipoxygenase at a non-active-site pocket and blocks it without the redox mechanism that makes zileuton complicated as a probe, and without the receptor-level competition that limits montelukast’s utility for dissecting leukotriene biosynthesis from downstream signaling. For an investigator trying to isolate that specific step, the mechanistic distinction matters. The multi-target overlay adds pharmacological texture: NF-kappaB suppression through direct IKKalpha and IKKbeta inhibition, topoisomerase I and IIalpha inhibition, leukocyte elastase inhibition, complement modulation. That’s more depth than most plant-derived anti-inflammatories can claim with a straight face.

But here’s the thing: this is frankincense. The Ayurvedic tradition stretches back centuries, and the 5-LOX pharmacology was characterized in the 1990s. The clinical evidence base is real and unusually coherent for a natural product. The Kimmatkar 2003 OA trial, Gupta 2014 asthma data, the IBD head-to-head against mesalazine, the Kirste 2011 radiation-induced cerebral edema signal at 4200 mg daily showing greater-than-75-percent edema reduction in 60 percent of patients – that’s multiple labs, multiple indications, reasonable methodology. It moves the compound well above the BPC-157 single-lab tier on evidence quality. But the core science is done. Nobody writing a 2025 grant is proposing to characterize AKBA’s mechanism; thats a closed chapter.

The differentiation picture is mixed. Among natural anti-inflammatories, boswellic acids stand out for mechanism specificity that curcumin (terrible bioavailability, contested mechanism), omega-3s (broad and non-specific), and willow bark (essentially salicylate) can’t match. The Aflapin self-emulsifying formulation and 5-Loxin standardized extract work has actually solved some of the oral bioavailability problem – KBA and AKBA get hit hard by CYP3A4-mediated first-pass and carboxylesterase 2-mediated deacetylation, so reliable plasma exposure requires either a lipid-rich context or a quality standardized extract. That practical detail matters for anyone designing an in-vivo protocol. Still, in the broader anti-inflammatory space, approved pharmaceuticals with better selectivity and cleaner pharmacokinetics outcompete on every clinical dimension.

we think the honest research case here is narrow but real: AKBA is a legitimate probe for 5-LOX-specific leukotriene biology when you need to avoid zileuton’s redox confounds. The oncology-supportive angle – cerebral edema reduction, topoisomerase inhibition data in glioma models – merits continued follow-up without being ready for primary-mechanism claims. But as a research program centerpiece in 2025, the compound has already delivered most of what it’s going to deliver. It earns its place in a comprehensive anti-inflammatory toolkit as a well-characterized, mechanism-specific tool, not as a frontier compound. The score reflects exactly that: solid but mature, useful but not exciting.

Novelty

20

Mechanism promise

50

In-category differentiation

42

Evidence quality

55

Translational signal

50

Research bench value

42

Rationale AKBA earns credit for a legitimately interesting allosteric 5-LOX mechanism and an unusually coherent multi-indication clinical record for a plant-derived compound, but the core pharmacology was characterized in the 1990s by Ammon’s group at Tubingen and the frontier has moved well past it; novelty is essentially nil, which drags the overall down despite solid evidence scores.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Pentacyclic triterpenic acid from Boswellia serrata oleogum resin with selective 5-lipoxygenase inhibition and pleiotropic anti-inflammatory activity

A family of ursane- and oleanane-type pentacyclic triterpenes isolated from Boswellia serrata frankincense resin, distinguished by noncompetitive allosteric inhibition of 5-lipoxygenase and convergent anti-inflammatory activity through NF-kappaB suppression, topoisomerase inhibition, and leukotriene biosynthesis blockade.

Abstract

Boswellic acids are a family of pentacyclic triterpenic acids isolated from the oleogum resin (frankincense) of Boswellia serrata and related species (B. carterii, B. sacra, B. papyrifera) that have been used in Ayurvedic medicine for centuries under the name Salai guggal and are now recognized as pharmacologically active anti-inflammatory agents with a distinct mechanism of action centered on selective, noncompetitive, allosteric inhibition of 5-lipoxygenase (5-LOX). The family comprises four principal bioactive congeners: beta-boswellic acid (beta-BA), 11-keto-beta-boswellic acid (KBA), 3-O-acetyl-beta-boswellic acid (ABA), and 3-O-acetyl-11-keto-beta-boswellic acid (AKBA), with AKBA representing the most potent 5-LOX inhibitor (IC50 approximately 1.5 micromolar in human neutrophils) and the primary pharmacologically characterized congener. The 5-LOX inhibition by AKBA proceeds through an allosteric, nonredox, noncompetitive mechanism that is unique among clinically studied leukotriene synthesis inhibitors and distinguishes the boswellic acid class from both the redox-type 5-LOX inhibitors (zileuton) and the competitive cysteinyl leukotriene receptor antagonists (montelukast, zafirlukast). Beyond 5-LOX inhibition, boswellic acids exert convergent anti-inflammatory activity through suppression of NF-kappaB signaling via direct inhibition of IkappaB kinases (IKKalpha and IKKbeta), inhibition of human leukocyte elastase, inhibition of topoisomerases I and IIalpha, modulation of complement system activation, and suppression of proinflammatory cytokine release including tumor necrosis factor alpha, interleukin-1 beta, and interleukin-6. Pharmacokinetics in humans are characterized by poor oral bioavailability of the keto-boswellic acids (KBA and AKBA) attributable to extensive first-pass hepatic metabolism via CYP3A4-mediated hydroxylation and carboxylesterase 2-mediated deacetylation, with plasma elimination half-lives of approximately 6 hours. Concomitant administration with a lipid-rich meal substantially improves absorption. Clinical evidence from randomized controlled trials supports efficacy in osteoarthritis (pain reduction and functional improvement at 100 to 250 mg AKBA-enriched extract daily), bronchial asthma (improvement in 70 percent of patients at 300 mg three times daily), inflammatory bowel disease (Crohn’s disease and ulcerative colitis, with response rates comparable to mesalazine), and radiation-induced cerebral edema (greater than 75 percent edema reduction in 60 percent of patients at 4200 mg daily). The compound class is generally well tolerated, with the principal adverse events being mild gastrointestinal discomfort (nausea, acid reflux, diarrhea) and rare allergic dermatitis. This monograph reviews the chemistry, structural pharmacology, and biosynthesis of the boswellic acid family; the multi-target mechanism of action in molecular detail; the comprehensive human pharmacokinetic record including bioavailability enhancement strategies; the clinical evidence base across osteoarthritis, asthma, inflammatory bowel disease, cerebral edema, and oncology-supportive indications; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse-event signal; and a comparative assessment of five alternative anti-inflammatory natural compounds against boswellic acids on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1495Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 13, 2026
SkQ1

Plain-language summaryIntrigue 67 / 100

SkQ1 (Visomitin) is the Russian answer to MitoQ: a mitochondria-targeted antioxidant that uses a positively charged triphenylphosphonium tail to drag plastoquinone, an antioxidant from plant chloroplasts, deep into the mitochondrial inner membrane where oxidative damage actually happens. The molecule was developed by Vladimir Skulachev, one of the giants of mitochondrial bioenergetics, and his group has produced extensive preclinical data in aging models. It is approved as eye drops in Russia for dry eye disease, with measurable clinical benefit. The lifespan and longevity data come almost entirely from Skulachev’s lab, which is the principal weakness of the file. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

51/100

Elegant rechargeable mitochondrial antioxidant; broad single-lab preclinical, Phase 3 failures in primary indication

Look, the mechanism here is genuinely clever. The triphenylphosphonium cation exploits the roughly 180-millivolt mitochondrial membrane potential to drive electrophoretic accumulation estimated at 10^8-fold above extracellular concentrations – thats a real selectivity story, not a rounding error. What sets SkQ1 apart from MitoQ is the plastoquinone headgroup rather than ubiquinone: it intercalates near cardiolipin fatty acid chains, and the rechargeable cycle regenerated by Complex I at the IQ site and Complex III at the Qi site means this isnt a stoichiometric scavenger burning itself out. Nanomolar external concentrations, sustained catalytic activity. That’s elegant chemistry and we credit it heavily on mechanism.

The Skulachev group at Moscow State built an unusually broad preclinical portfolio: lifespan extension across fungi, crustaceans, Drosophila, killifish, and multiple rodent strains; prevention and reversal of cataracts, retinopathy, osteoporosis, and Alzheimer-like pathology in the OXYS rat; cardio-, nephro-, and neuroprotection across acute injury models; ferroptosis suppression in cisplatin and ischemia-reperfusion kidney models. The breadth is real and mechanistic consistency across model systems is genuinely encouraging. Here’s the thing, though: almost all of this traces back to a single research consortium. Skulachev’s lab defines the literature in a way thats uncomfortably close to what we say about BPC-157 or Epitalon. Independent replication outside the Russian program is sparse, and for a compound making longevity claims across six phyla, that’s a hard credibility ceiling.

The clinical picture is mixed in a way that matters. Visomitin got Russian Ministry of Health approval in 2011 for dry eye syndrome, and the US Phase 2 trial in 91 subjects showed statistically significant improvement in corneal fluorescein and lissamine green staining – a genuine positive signal. Then VISTA-1 and VISTA-2 happened: 452 and 610 subjects respectively, primary co-endpoints missed in both. VISTA-2 showed significance on a pre-specified secondary endpoint in a Schirmer’s-defined subpopulation, which is exactly the kind of result that keeps a compound alive in funding conversations but doesnt move the scientific needle much. Phase 3 failures in the primary indication are evidence-quality limiters, full stop.

Where SkQ1 retains real value is as a bench probe. For research programs interrogating mitochondrial ROS contributions to age-related pathology, ferroptosis mechanisms, ischemia-reperfusion injury, or mtROS-driven inflammation, SkQ1 is a chemically well-characterized, concentration-dependent tool with a documented safety window and no CYP450 induction liability. The rechargeable mechanism is a genuine feature in chronic-exposure experimental designs. It belongs in a serious mitochondria-research toolkit alongside SS-31 and MitoQ, though it doesnt clearly dominate either. The 51 reflects a compound with an interesting mechanism and genuine preclinical breadth that hasn’t cleared the clinical bar, backed by literature that needs substantially more independent replication before earning a higher ranking.

Novelty

48

Mechanism promise

72

In-category differentiation

45

Evidence quality

40

Translational signal

38

Research bench value

60

Rationale The rechargeable TPP-driven mitochondrial accumulation mechanism scores well on mechanism promise, and the preclinical breadth across six phyla is genuine, but the evidence base is heavily Skulachev-consortium-dominated and Phase 3 ophthalmology failures (VISTA-1/VISTA-2) meaningfully constrain both evidence quality and translational signal; bench utility for mtROS research is solid but not indispensable.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Mitochondria-targeted plastoquinone-based antioxidant conjugated to a penetrating lipophilic cation (triphenylphosphonium)

A rechargeable, mitochondria-accumulating plastoquinone derivative developed at Lomonosov Moscow State University as a direct scavenger of reactive oxygen species at the inner mitochondrial membrane, with preclinical geroprotective, cytoprotective, and anti-inflammatory activity across multiple organ systems and a registered ophthalmic formulation (Visomitin) for dry eye syndrome.

Abstract

SkQ1 (10-(6′-plastoquinonyl)decyltriphenylphosphonium), designated a “Skulachev ion” after its principal developer Vladimir P. Skulachev, is a synthetic mitochondria-targeted antioxidant composed of a plastoquinone moiety linked by a ten-carbon aliphatic chain to a triphenylphosphonium cation. The triphenylphosphonium group exploits the large negative-inside mitochondrial membrane potential (approximately 180 millivolts) to drive electrophoretic accumulation of the compound within the mitochondrial matrix at concentrations estimated to reach 10(8)-fold above extracellular levels. Within the inner mitochondrial membrane, the plastoquinone headgroup intercalates near the cardiolipin fatty acid chains and directly quenches peroxyl radicals, with regeneration of the reduced (antioxidant-active) form by Complex I at the IQ site and by Complex III at the Qi site of the electron transport chain. This rechargeable antioxidant cycle distinguishes SkQ1 from stoichiometric scavengers and positions it as a catalytic antioxidant with sustained activity at nanomolar external concentrations. The compound was developed beginning in the early 2000s at the A. N. Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, within a research framework centered on Skulachev’s hypothesis that aging represents a form of programmed organismal death (phenoptosis) mediated by mitochondrial reactive oxygen species (mtROS). Preclinical studies in organisms spanning fungi (Podospora anserina), crustaceans (Ceriodaphnia affinis), insects (Drosophila melanogaster), fish (Nothobranchius furzeri), and mammals (mice and rats) have demonstrated lifespan extension, delay or reversal of age-related pathologies, and suppression of mtROS-driven tissue damage under a variety of experimental conditions. In the senescence-accelerated OXYS rat strain, SkQ1 prevented or reversed cataracts, retinopathy resembling age-related macular degeneration, osteoporosis, and neurodegenerative phenotypes resembling Alzheimer’s disease. In outbred and inbred mouse strains, SkQ1 extended median and maximum lifespan under non-specific-pathogen-free housing conditions, with effect sizes dependent on ambient pathogen exposure. The compound prevented rapid death caused by mechanistically diverse acute shocks including bacterial lipopolysaccharide, intravenous mitochondrial injection, cold exposure, and toxic insult. The ophthalmic formulation of SkQ1 (Visomitin, 0.155 micrograms per milliliter ophthalmic solution) was approved by the Russian Ministry of Health in December 2011 for the treatment of dry eye syndrome and early cataracts. In the United States, Mitotech S.A. advanced SkQ1 ophthalmic solution through a positive Phase 2 clinical trial demonstrating statistically significant improvement in corneal fluorescein staining and lissamine green staining relative to placebo in 91 subjects with mild to moderate dry eye disease. Two subsequent Phase 3 studies (VISTA-1, 452 subjects; VISTA-2, 610 subjects) did not meet their co-primary endpoints, although VISTA-2 demonstrated statistically significant superiority in a pre-specified secondary endpoint of central corneal fluorescein staining change in a Schirmer’s score-defined subpopulation. Phase 1 oral formulation studies were conducted in Russia in 2016. Preclinical pharmacology extends beyond ophthalmology to include cardioprotection (hemorrhagic shock, doxorubicin-induced cardiomyopathy), nephroprotection (cisplatin-induced and ischemia-reperfusion acute kidney injury with ferroptosis inhibition), neuroprotection (stroke, Alzheimer’s disease models in OXYS rats), hepatoprotection, suppression of experimental colitis and autoimmune arthritis, wound healing acceleration, tumor growth inhibition in fibrosarcoma and rhabdomyosarcoma models, and antibacterial activity at micromolar concentrations. Safety pharmacology in rats and dogs has demonstrated a wide therapeutic window with no adverse effects on the central nervous system, cardiovascular system, or respiratory system at doses orders of magnitude above the efficacious range. The compound does not induce hepatic cytochrome P450 enzymes. This monograph reviews the chemistry, structural pharmacology, and rechargeable antioxidant mechanism of SkQ1; the comprehensive preclinical evidence across geroprotective, cytoprotective, and anti-inflammatory applications; the clinical evidence base in dry eye disease; the pharmacokinetic characteristics; sourcing and quality considerations; reconstitution and handling protocols; stack-interaction implications; the adverse-event and safety profile; and a structured comparative assessment of five mitochondria-targeted antioxidant candidates against SkQ1 on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1467Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 13, 2026
Beta-Lapachone

Our opinion on this compoundEstablished, active research

60/100

Elegant NQO1-dependent cytotoxic with genuine tumor-selectivity logic and a mixed, instructive clinical record

Look, beta-lapachone earns genuine respect as a mechanistic archetype. The NQO1-dependent futile redox cycling story is one of the more elegant tumor-selectivity concepts in the cytotoxic literature: NQO1 is overexpressed 5- to 100-fold in most solid cancers relative to matched normal tissue, and this compound exploits that differential by spinning through a hydroquinone/quinone cycle that consumes roughly 60 moles of NADH per mole of drug over a two-hour window. Normal cells, which largely lack NQO1 expression, are simply inert to it at pharmacologically achievable concentrations. That kind of substrate-level selectivity, enforced by an endogenous enzyme rather than a prodrug chemistry trick, is legitimately interesting.

What we find even more compelling is what happens downstream. The ROS burst from futile cycling drives massive DNA single-strand breaks, which triggers PARP1 hyperactivation. PARP1 then runs through the cellular NAD+ pool into branched poly(ADP-ribose) so fast the cell can’t maintain ATP. Mu-calpain activates, AIF translocates from mitochondria to nucleus, and the cell dies by programmed necrosis, not classical apoptosis. That matters because it bypasses p53 status, Bcl-2 family expression, and caspase activation entirely. In cancers where apoptosis resistance drives chemotherapy failure, thats a real research question, not a cosmetic one.

The clinical record complicates the enthusiasm considerably. ArQule advanced the hydroxypropyl-beta-cyclodextrin complex (ARQ 501) through Phase I, established an MTD of 390 mg/m2 as a 2-hour infusion every other week, then ran a Phase II in treatment-naive unresectable pancreatic adenocarcinoma with gemcitabine. The result was disease stabilization, not objective responses. In PDAC thats not nothing, but its not registration data either. The dose-limiting toxicities, hemolytic anemia and methemoglobinemia from off-target redox cycling via cytochrome b5 reductase in erythrocytes, are a genuine translation bottleneck that ARQ 761’s improved formulation is still working around. The erythrocyte toxicity problem isn’t a formulation artifact; it’s an intrinsic liability of futile cycling in cells that express b5 reductase at high levels regardless of NQO1 status.

As a bench tool, though, beta-lapachone has real staying power. It’s the canonical NQO1 substrate. The dicoumarol rescue experiment is a clean mechanistic control you can’t run with anything else. Investigators working on PARP1 biology, programmed necrosis versus apoptosis switching, NQO1-targeted prodrug delivery, or NAD+ metabolism under oxidative stress all have a reason to keep this on the shelf. The metabolic angle is also underappreciated: the NQO1-mediated NADH oxidation story driving adipose tissue browning is a distinct research program from the oncology work, and the MB12066 first-in-human PK data gives it some early translational grounding.

Honestly, the score here reflects a compound with a genuinely interesting and well-validated mechanism, a credible but ultimately disappointing clinical run in one of the hardest tumor types to treat, and durable bench value as the reference substrate for an important and druggable enzyme. It’s not a dead end. But the path to clinical utility is harder than the elegant mechanism would suggest, and serious investigators should go in with clear eyes about what the Phase II data actually showed.

Novelty

55

Mechanism promise

75

In-category differentiation

70

Evidence quality

48

Translational signal

42

Research bench value

68

Rationale Beta-lapachone scores well on mechanism and differentiation because the NQO1 futile redox cycling/PARP1 hyperactivation/programmed necrosis axis is mechanistically clean and tumor-selective in a way most cytotoxics aren’t; evidence and translational scores are tempered by Phase II failure in pancreatic cancer and a real toxicity bottleneck in erythrocytes, while bench value remains high as the canonical NQO1 substrate.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

NQO1-bioactivatable ortho-naphthoquinone with selective tumor cytotoxicity through futile redox cycling and PARP1 hyperactivation

A naturally derived 1,2-naphthoquinone from the lapacho tree, bioactivated selectively by NAD(P)H:quinone oxidoreductase 1 to induce tumor-specific programmed necrosis through futile redox cycling, massive reactive oxygen species generation, DNA damage, PARP1 hyperactivation, and catastrophic NAD+/ATP depletion.

Abstract

Beta-lapachone is a naturally occurring ortho-naphthoquinone originally isolated from the heartwood of Tabebuia avellanedae (pau d’arco, lapacho) and synthesized from the prenylated naphthoquinone lapachol by acid-catalyzed cyclization. The compound is the canonical substrate of NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase, EC 1.6.5.2), a two-electron reductase that is overexpressed 5- to 100-fold in the majority of solid human cancers, including non-small cell lung, pancreatic ductal adenocarcinoma, breast, prostate, and head and neck squamous cell carcinomas, relative to matched normal tissue. NQO1-mediated two-electron reduction of beta-lapachone produces an unstable hydroquinone that spontaneously autoxidizes back to the parent quinone in a futile redox cycle consuming approximately 60 moles of NAD(P)H per mole of drug over a 2-hour exposure window. This cycle generates massive superoxide and hydrogen peroxide fluxes within the tumor cell, producing extensive oxidative DNA damage (predominantly single-strand breaks and oxidized bases) that triggers hyperactivation of poly(ADP-ribose) polymerase 1 (PARP1) in the presence of elevated nuclear calcium. PARP1 hyperactivation consumes the cellular NAD+ pool into branched poly(ADP-ribose) polymers, producing catastrophic NAD+ and ATP depletion, mu-calpain activation, apoptosis-inducing factor (AIF) translocation from mitochondria to the nucleus, and programmed necrosis that is mechanistically distinct from classical apoptosis and independent of caspase activation, p53 status, and Bcl-2 family protein expression. The NQO1 dependence of the cytotoxic mechanism confers tumor selectivity: NQO1-negative cells (including most normal tissues) are resistant to beta-lapachone at pharmacologically achievable concentrations, and dicoumarol (an NQO1 inhibitor) completely abrogates cytotoxicity in NQO1-positive cancer cell lines. Beta-lapachone was advanced into clinical development as ARQ 501 (an intravenous hydroxypropyl-beta-cyclodextrin inclusion complex) by ArQule, Inc. and subsequently as ARQ 761 (an improved intravenous formulation) by the University of Texas Southwestern Medical Center. Phase I trials in patients with advanced solid tumors established a maximum tolerated dose of 390 mg/m2 as a 2-hour intravenous infusion every other week, with dose-limiting toxicities of hemolytic anemia and methemoglobinemia attributable to off-target redox cycling interaction with cytochrome b5 reductase in erythrocytes. A Phase II trial of ARQ 501 in combination with gemcitabine in treatment-naive unresectable pancreatic adenocarcinoma demonstrated disease stabilization but did not produce objective tumor responses sufficient for registration. A separate clinical derivative, MB12066, was developed for metabolic syndrome indications and completed first-in-human pharmacokinetic and tolerability studies at oral doses of 10 to 400 mg. Beyond anticancer applications, beta-lapachone exhibits anti-inflammatory activity through suppression of NF-kappaB-driven cytokine expression in activated macrophages and microglia, anti-obesity effects through stimulation of energy expenditure and white adipose tissue browning via NQO1-dependent NADH oxidation, and antimicrobial activity against Trypanosoma cruzi and Mycobacterium tuberculosis. This monograph reviews the chemistry, synthesis, and natural product origin of beta-lapachone; the NQO1-dependent futile redox cycling mechanism in molecular detail; the comprehensive pharmacokinetic record including formulation challenges; the preclinical and clinical evidence base across oncology, metabolic, and inflammatory indications; the reconstitution, sourcing, and handling considerations for laboratory work; and a comparative assessment of five NQO1-targeted or naphthoquinone-class compounds against beta-lapachone on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation). The compound is not approved by any regulatory authority for any therapeutic indication. It is available as a research-grade preparation; investigators should obtain analytical confirmation of identity and purity on every lot.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1487Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 13, 2026
AF710B

Our opinion on this compoundNovel, promising

62/100

Dual allosteric M1 and sigma-1R agonist with multi-lab disease-modifying preclinical and confirmed Phase 1 human safety

Look, AF710B is one of the more intellectually interesting compounds in the cholinergic AD space right now, and the dual-target mechanism is the reason. Earlier orthosteric M1 agonists from the same Fisher group at IIBR, AF267B and cevimeline, showed real procognitive and anti-amyloidogenic activity in preclinical work but kept running into the same wall: insufficient M1 selectivity and dose-limiting cholinergic toxicity. AF710B sidesteps that wall by working allosterically, potentiating endogenous acetylcholine at the M1 receptor rather than competing with it, which preserves the downstream ERK1/2 and CREB signaling you want while avoiding the cardiovascular and GI adverse effects that crippled the earlier series. The selectivity screen at 10 micromolar across 83 receptors, ion channels, and transporters came back clean. Thats a genuinely useful pharmacological profile, especially compared to xanomeline, which required coadministration with a peripheral antimuscarinic just to become tolerable.

The sigma-1 receptor piece is what keeps this from being just a cleaner orthosteric. Sigma-1R is an ER chaperone concentrated at the mitochondria-associated membrane, and its activation does several things simultaneously: normalizes calcium transfer between the ER and mitochondria, modulates the unfolded protein response, suppresses neuroinflammation through antiapoptotic cascades. The dendritic spine rescue data in presenilin-1 and APP knock-in neuronal cultures is worth noting here. Mushroom spine loss is one of the earliest structural correlates of synaptic dysfunction in AD models, and recovering that population via sigma-1R agonism points at a neuroprotective axis independent of the cholinergic one. Thats two mechanistically distinct handles on AD pathology in a single molecule.

The preclinical case is multi-lab and, honestly, unusually clean for this space. Fisher et al. 2016 in 3xTg-AD mice showed simultaneous reduction in BACE1, GSK3-beta activity, amyloid plaque, phospho-tau, and neuroinflammatory markers alongside cognitive improvement in the Morris water maze. Hall et al. 2018 replicated the core findings in the McGill-R-Thy1-APP rat at 10 micrograms per kilogram oral, and the effects persisted through a five-week drug washout. Thats the disease-modification signal, not symptomatic masking. Bhatt et al. 2024 rounded it out with early-treatment prevention data in the same rat line. Three groups, two species, two transgenic models. Not a single-consortium story.

Where we dont get excited is the clinical side. Phase 1 in 42 healthy volunteers confirmed safety and linear, dose-proportional PK with a half-life around 3.5 hours. The Phase 2 in schizophrenia (ANAVEX3-71-SZ-001) reported positive topline results in late 2025, specifically GFAP reduction and encouraging EEG biomarker trends, which is interesting but its a different indication with soft endpoints. No AD Phase 2 exists. The FTD orphan designation signals regulatory awareness, not clinical proof. For a bench-scale investigator, what’s here is a well-characterized allosteric M1/sigma-1R dual probe with clean selectivity data and enough preclinical depth to support serious mechanistic work. The outstanding question is whether any of this translates in AD patients, and that answer doesnt exist yet.

Novelty

68

Mechanism promise

78

In-category differentiation

65

Evidence quality

50

Translational signal

42

Research bench value

58

Rationale The allosteric M1 selectivity plus sigma-1R chaperone dual mechanism is genuinely distinctive from orthosteric predecessors and current muscarinic competitors; multi-lab, two-species preclinical with disease-modification signal and Phase 1 PK confirmation justify solid novel-promising placement, but absent any AD-indication Phase 2 data the translational score stays modest.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Allosteric M1 muscarinic acetylcholine receptor agonist and sigma-1 receptor agonist with disease-modifying preclinical efficacy in Alzheimer’s disease models

A dual-target allosteric M1 muscarinic and sigma-1 receptor agonist developed at the Israel Institute for Biological Research and advanced by Anavex Life Sciences as ANAVEX 3-71, distinguished from earlier orthosteric muscarinic agonists by allosteric M1 selectivity, picomolar-range potency, sigma-1 chaperone engagement, and disease-modifying activity across amyloid, tau, and neuroinflammatory pathologies in transgenic rodent models of Alzheimer’s disease.

Abstract

AF710B (ANAVEX 3-71) is a highly potent and selective allosteric agonist of the M1 subtype of the muscarinic acetylcholine receptor (M1 mAChR) and a concurrent agonist of the sigma-1 receptor (sigma-1R), first reported by Fisher et al. (2016) in Neurodegenerative Diseases as a next-generation candidate for cognitive enhancement and disease modification in Alzheimer’s disease [1]. The compound emerged from a decades-long medicinal chemistry program at the Israel Institute for Biological Research (IIBR) that previously produced the orthosteric M1 agonists AF102B (cevimeline, approved for Sjogren’s syndrome), AF267B, and AF292, each of which demonstrated procognitive and anti-amyloidogenic activity in preclinical and early clinical settings but was limited by insufficient M1 selectivity, dose-limiting cholinergic adverse events, or both. AF710B was designed to overcome these limitations through an allosteric mechanism of M1 receptor engagement: at nanomolar concentrations the compound potentiates the binding and efficacy of the endogenous agonist acetylcholine (and of the reference orthosteric agonist carbachol) at the M1 receptor, amplifying downstream signaling through phospho-ERK1/2 and phospho-CREB pathways without producing the gastrointestinal and cardiovascular cholinergic toxicity that constrained the earlier orthosteric series [1, 2]. Selectivity screening at 10 micromolar against 83 additional G-protein-coupled receptors, ion channels, and transporters produced no significant off-target hits, establishing a pharmacological selectivity profile substantially cleaner than that of xanomeline and other earlier M1-preferring agonists [1]. The sigma-1 receptor agonism adds a second, mechanistically independent neuroprotective axis. Sigma-1R is an endoplasmic reticulum chaperone protein concentrated at the mitochondria-associated endoplasmic reticulum membrane (MAM), where it regulates calcium transfer between the endoplasmic reticulum and mitochondria, modulates the unfolded protein response, and activates anti-inflammatory and antiapoptotic signaling cascades [3, 4]. Activation of sigma-1R by AF710B has been linked to rescue of mushroom spine loss in presenilin-1 knock-in and APP knock-in neuronal cultures, reduction of neuroinflammatory markers, and normalization of brain-derived neurotrophic factor (BDNF) signaling in transgenic models [1, 5]. In the seminal Fisher et al. (2016) study, AF710B administered to female 3xTg-AD mice at 10 micrograms per kilogram intraperitoneally daily for two months mitigated cognitive impairment in the Morris water maze and reduced BACE1 expression, GSK3-beta activity, p25/CDK5 levels, neuroinflammation, soluble and insoluble amyloid-beta 40 and 42, amyloid plaques, and phosphorylated tau pathology [1]. A subsequent study by Hall et al. (2018) in Alzheimer’s and Dementia extended these findings to the McGill-R-Thy1-APP transgenic rat model, demonstrating that chronic oral AF710B at 10 micrograms per kilogram daily for 4.5 months in 13-month-old (post-plaque) rats reversed cognitive deficits, reduced hippocampal amyloid plaque burden and cortical amyloid-beta 40 and 42 levels, decreased neuroinflammatory markers, increased cerebrospinal fluid amyloid clearance, and elevated the synaptic marker synaptophysin [6]. The disease-modifying character of the effect was underscored by its persistence through a five-week drug washout period following treatment cessation. A third study (Bhatt et al., 2024, Neurobiology of Aging) confirmed that early treatment with AF710B in the same rat model prevented cognitive decline when treatment was initiated before overt plaque deposition [7]. Anavex Life Sciences Corporation acquired exclusive worldwide rights to the AF710B intellectual property in 2014 and advanced the compound under the designation ANAVEX 3-71 through a first-in-human Phase 1 single ascending dose study in 42 healthy volunteers (2020 to 2021), which demonstrated safety and tolerability at oral doses of 5 to 200 mg with no serious adverse events, no clinically significant electrocardiogram changes, and linear, dose-proportional pharmacokinetics with a mean terminal elimination half-life of approximately 3.56 hours [8, 9]. A Phase 1b study subsequently confirmed the bioavailability of a once-daily oral tablet formulation. In 2024, Anavex initiated a placebo-controlled Phase 2 study (ANAVEX3-71-SZ-001) in adults with schizophrenia, and in October 2025 reported positive topline results demonstrating safety, tolerability, reduction in the neuroinflammatory biomarker glial fibrillary acidic protein (GFAP), and encouraging trends in EEG and event-related potential biomarkers [10, 11]. The compound has received orphan drug designation from the FDA for frontotemporal dementia. No registration-enabling Phase 3 trial has been completed for any indication as of the most recent monograph revision. This monograph documents the chemistry, synthesis, dual-receptor pharmacology, pharmacokinetics, preclinical and clinical evidence, sourcing and handling considerations, stack interactions, adverse-event profile, and a structured comparative assessment of AF710B against five muscarinic and sigma-1 receptor candidates on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1456Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 13, 2026
Blarcamesine

Our opinion on this compoundEstablished, active research

59/100

Sigma-1/muscarinic dual agonist with real Phase 2b/3 signal, but EMA rejection complicates the translational story

Look, blarcamesine is genuinely one of the more interesting small molecules to emerge from the neurodegeneration drug development space in the past decade. It targets the sigma-1 receptor as its primary engagement — an endoplasmic reticulum chaperone sitting at mitochondria-associated membranes (MAMs) that modulates calcium flux, ER stress responses, autophagy, and neuroinflammation — with muscarinic acetylcholine receptor co-activity layered on top. The MAM hypothesis in Alzheimer’s biology is serious science, not fringe speculation, and blarcamesine is the most clinically advanced sigma-1 agonist that has ever existed.

The Phase 2b/3 ANAVEX2-73-AD-004 trial enrolled 508 patients across 52 centers in five countries and reported statistically significant slowing of ADAS-Cog13 decline at 48 weeks — 38.5% slowing at the 50 mg dose (P = 0.021). Volumetric MRI showed a 63.5% reduction in grey matter atrophy versus placebo. The AVATAR Phase 3 in adult Rett syndrome hit its primary endpoint with a Cohen’s d of 1.91; thats a large effect size by any standard. Phase 2 in Parkinson’s disease dementia showed dose-dependent cognitive signal on CDR computerized assessment. The pediatric Rett trial (EXCELLENCE) missed statistical separation, likely on placebo response. Multi-indication, reasonably powered, real data across multiple Phase 2 and Phase 3 programs.

Here’s the thing though. The EMA accepted a Marketing Authorization Application in December 2024, and the CHMP issued a negative opinion in December 2025 — benefit wasn’t convincingly demonstrated in patients without SIGMAR1 gene mutations, and tolerability-driven discontinuation rates were specifically cited. The application was withdrawn in March 2026. That’s a significant development that we can’t paper over. It doesn’t invalidate the mechanism; the signal in mutation-positive patients looks real, and the Rett syndrome data stands largely on its own. But an independent regulatory body examined the full-population analysis and found it insufficient. That finding pulls down the translational and differentiation scores meaningfully.

What we think the real research angle is now: the SIGMAR1 genotype question. Differential pharmacological benefit based on receptor gene variation is a genuinely under-explored precision pharmacology problem, and the clinical data has inadvertently sharpened it. For investigators working on ER proteostasis, MAM biology, or genotype-stratified neuromodulation, blarcamesine is a well-characterized probe with PET-confirmed receptor occupancy via [18F]FTC-146, four-year continuous-dosing safety data, and a defined pharmacokinetic profile including the ANAVEX19-144 metabolite. Cutamesine and fluvoxamine don’t offer the dual muscarinic co-engagement or anything near this clinical validation depth; the sigma-1 field has no real comparator at this stage. The regulatory outcome probably routes blarcamesine toward precision-indication repositioning rather than broad approval, and from a bench science standpoint, thats a more tractable and scientifically precise place to be working from.

Novelty

58

Mechanism promise

68

In-category differentiation

58

Evidence quality

52

Translational signal

52

Research bench value

62

Rationale The MAM-targeted sigma-1 agonism mechanism is genuinely multi-target and the multi-phase clinical program across Alzheimer’s, Rett syndrome, and PD dementia shows real signals; however, the CHMP’s December 2025 negative opinion and March 2026 application withdrawal — based on insufficient evidence in SIGMAR1 mutation-negative patients and tolerability-driven discontinuation — significantly limit both the translational score and the differentiation case. As a bench probe, blarcamesine remains the most clinically validated sigma-1 receptor tool and the SIGMAR1 genotype precision angle is a live, underexplored research question that the failed approval actually sharpens.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Sigma-1 receptor agonist and mixed muscarinic receptor modulator (aminotetrahydrofuran derivative)

An orally bioavailable aminotetrahydrofuran derivative developed by Anavex Life Sciences as a sigma-1 receptor agonist with muscarinic receptor co-activity, investigated for disease modification in Alzheimer’s disease, Rett syndrome, Parkinson’s disease dementia, and other neurodegenerative and neurodevelopmental conditions.

Abstract

Blarcamesine (ANAVEX 2-73; tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine) is a small-molecule sigma-1 receptor (SIGMAR1) agonist and mixed muscarinic acetylcholine receptor modulator that has advanced through Phase 2b/3 clinical development for early Alzheimer’s disease, Phase 3 for adult Rett syndrome, Phase 2 for Parkinson’s disease dementia, and Phase 2/3 for pediatric Rett syndrome. The compound was first characterized pharmacologically by Villard, Espallergues, Keller, Vamvakides, and Maurice (2011) as a novel aminotetrahydrofuran derivative with anti-amnesic and neuroprotective activity mediated through dual engagement of sigma-1 and muscarinic acetylcholine receptors. The sigma-1 receptor is an endoplasmic reticulum chaperone protein localized at mitochondria-associated endoplasmic reticulum membranes (MAMs) that modulates calcium homeostasis, endoplasmic reticulum stress responses, mitochondrial function, autophagy, and neuroinflammation. Activation of SIGMAR1 by blarcamesine restores cellular proteostasis, reduces oxidative stress through suppression of reactive oxygen species, and promotes neuroplasticity through downstream modulation of brain-derived neurotrophic factor and glutamate signaling. In preclinical models, blarcamesine has demonstrated anti-amnesic activity in scopolamine- and dizocilpine-induced learning impairment paradigms, neuroprotection in the amyloid-beta(25-35) peptide injection mouse model of Alzheimer’s disease (blocking both cognitive impairment and hippocampal oxidative stress), amelioration of motor, sensory, and autonomic phenotypes in the Mecp2 mouse model of Rett syndrome, and dose-dependent sigma-1 receptor occupancy confirmed by positron emission tomography with the selective ligand [18F]FTC-146. The pivotal ANAVEX2-73-AD-004 Phase 2b/3 randomized, double-blind, placebo-controlled trial enrolled 508 patients with early Alzheimer’s disease across 52 centers in five countries and demonstrated that oral blarcamesine at 50 mg and 30 mg daily significantly slowed cognitive decline on the primary endpoint ADAS-Cog13 at 48 weeks (38.5% and 34.6% slowing versus placebo, respectively; P = 0.021 and P = 0.026) [1]. Co-primary analysis showed significant benefit on CDR-SB. Volumetric magnetic resonance imaging demonstrated significant reduction of whole brain atrophy by 37.6%, total grey matter atrophy by 63.5%, and lateral ventricular enlargement by 25.1% versus placebo. Plasma amyloid-beta 42/40 ratio increased significantly in the blarcamesine group (P = 0.048). Open-label extension data through four years of continuous treatment demonstrated sustained benefit on ADAS-Cog13 and ADCS-ADL, with a delayed-start analysis suggesting importance of early treatment initiation. The AVATAR Phase 3 trial in 33 adult patients with Rett syndrome (MECP2 mutation-positive) met primary (RSBQ AUC, P = 0.037; Cohen’s d = 1.91) and secondary (ADAMS, P = 0.010; CGI-I, P = 0.037) efficacy endpoints on once-daily oral dosing of up to 30 mg [2]. A proof-of-concept Phase 2 trial in 132 patients with Parkinson’s disease dementia showed dose-dependent cognitive improvement on the CDR computerized assessment system and improvement on MDS-UPDRS total score at 14 weeks [3]. The EXCELLENCE Phase 2/3 pediatric Rett syndrome trial in 92 patients showed numerical improvement in RSBQ but did not achieve statistical separation from placebo, possibly due to a high placebo response rate [4]. The safety profile across clinical programs is characterized by predominantly mild-to-moderate adverse events concentrated during the initial dose titration period. The most common treatment-emergent adverse events are dizziness (approximately 36% of treated patients in the Alzheimer’s disease program), confusional state (approximately 14%), balance disorder, and fatigue; these are generally transient (resolving within 7 to 11 days), manageable by titration schedule adjustment, and not associated with serious or life-threatening sequelae. No neuroimaging-related adverse events (such as amyloid-related imaging abnormalities) have been reported. Long-term safety data through four years of continuous dosing have not revealed new safety signals. The European Medicines Agency accepted a Marketing Authorization Application for blarcamesine in Alzheimer’s disease in December 2024, but the Committee for Medicinal Products for Human Use issued a negative opinion in December 2025 on grounds of insufficient demonstration of efficacy in patients without SIGMAR1 gene mutations and concerns regarding tolerability-driven treatment discontinuation. The application was subsequently withdrawn in March 2026. This monograph reviews the chemistry, structural class, and synthesis of blarcamesine; the sigma-1 receptor and muscarinic receptor pharmacology; the pharmacokinetic profile including the ANAVEX19-144 metabolite; the preclinical evidence base across Alzheimer’s, Rett syndrome, fragile X syndrome, and Parkinson’s disease models; the full clinical evidence base; sourcing considerations; reconstitution and handling; stack interactions; adverse events; and a comparative assessment of five sigma-1 receptor-active compounds against blarcamesine on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1461Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 13, 2026

←Previous Page

1 … 19 20 21 22 23 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.